Press release
Next Generation Antibody Therapeutics will Account for Revenues Worth US$ 6.75 Bn by 2022 End
According to a new market report published by Persistence Market Research “Global Market Study on Next-Generation Antibody Therapeutics: Biosimilar Antibody Products to Witness Highest Growth by 2022”, the global next-generation antibody therapeutics market is project to be valued at US$ 2,250.0 Mn by the end of 2015 and is expected to expand at a CAGR of 13.0% from 2015 to 2022, to account for US$ 6,761.1 Mn by 2022.Next-generation antibody therapeutics refers to improved antibody therapeutics with enhanced efficiency, greater safety, and improved delivery. Advancements in monoclonal antibody technologies have led to the development of next-generation therapeutic antibodies with reduced functional size, greater bifunctional properties, and low immunogenicity. Next-generation antibody-based therapeutics enhances existing properties of therapeutic antibodies for the treatment of various medical conditions such as cancer, infectious diseases, and autoimmune diseases.
Request to Sample of Report @ https://www.persistencemarketresearch.com/samples/3713
Globally, the next-generation antibody therapeutics market is witnessing significant growth due to technological advancements in antibody therapeutics and increasing the prevalence of chronic diseases. In addition, rising healthcare expenditure and growing R & D activities are driving the growth of the next-generation antibody therapeutics market. However, stringent regulatory requirements and long approval time for new drug restrains the growth of the market. Similarly, high costs of next-generation antibody therapeutics is a major concern for the market.
Request Report For TOC @ https://www.persistencemarketresearch.com/market-research/next-generation-antibody-therapeutics-market/toc
North America is the largest market for next-generation antibody therapeutics. This is mainly due to increasing prevalence of chronic diseases and increasing healthcare spending in the region. The North America next-generation antibody therapeutics market is projected to be valued at US$ 1,104.4 Mn by the end of 2015 and is expected to account for US$ 3,691.8 Mn by 2022 at a CAGR of 14.5%. On the basis of technology, biosimilar antibody products are the fastest growing segment. On the basis of therapeutic application, oncology is the largest segment in next-generation antibody therapeutics market.
Report Overview @ https://www.persistencemarketresearch.com/market-research/next-generation-antibody-therapeutics-market.asp
Roche, Seattle Genetics, Takeda, Dyax Corp., and Immunogen are some of the leading players in the global market of next-generation antibody therapeutics. Some of the other major players in next-generation antibody therapeutics market are Amgen, Inc., Biogen, Kyowa Hakko Kirin Co., Ltd., AstraZeneca, Pfizer, Inc., and Xencor, Inc.
About Us
Persistence Market Research (PMR) is a U.S.-based full-service market intelligence firm specializing in syndicated research, custom research, and consulting services. PMR boasts market research expertise across the Healthcare, Chemicals and Materials, Technology and Media, Energy and Mining, Food and Beverages, Semiconductor and Electronics, Consumer Goods, and Shipping and Transportation industries. The company draws from its multi-disciplinary capabilities and high-pedigree team of analysts to share data that precisely corresponds to clients’ business needs.
PMR stands committed to bringing more accuracy and speed to clients’ business decisions. From ready-to-purchase market research reports to customized research solutions, PMR’s engagement models are highly flexible without compromising on its deep-seated research values.
Contact
Persistence Market Research Pvt. Ltd
305 Broadway
7th Floor, New York City,
NY 10007, United States,
USA – Canada Toll Free: 800-961-0353
Email: sales@persistencemarketresearch.com
media@persistencemarketresearch.com
Web:www.persistencemarketresearch.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Next Generation Antibody Therapeutics will Account for Revenues Worth US$ 6.75 Bn by 2022 End here
News-ID: 946533 • Views: …
More Releases from Persistence Market Research
Microwave Absorbing Materials Market to Reach US$691.9 Million by 2032 - Persist …
The global microwave absorbing materials market is experiencing rapid growth due to the rising demand for electromagnetic interference control across multiple industries. As the integration of electronic systems in various applications continues to expand, managing electromagnetic emissions has become critical for ensuring efficient operation, reliability, and safety. Microwave absorbing materials are designed to reduce unwanted electromagnetic waves by absorbing and dissipating their energy. These advanced materials play a key role…
Polytetrahydrofuran Market Valued at US$5.6 Billion in 2025, Projected to Reach …
The global chemical industry is undergoing a significant transformation as innovation, sustainability, and performance requirements reshape product development. Among the many specialty polymers driving this evolution, Polytetrahydrofuran has emerged as a highly versatile material used across diverse industrial applications. Commonly known as PolyTHF or PTMEG, this polymer is a key intermediate for producing elastic fibers, thermoplastic polyurethanes, coatings, and elastomers. Its ability to impart flexibility, resilience, and abrasion resistance makes…
Europe Automotive Heat Exchanger Market to Reach US$ 8.9 Billion by 2031, Exhibi …
The Europe automotive heat exchanger market has been witnessing steady growth, driven by the rapid evolution of vehicle technologies, stricter emission norms, and the widespread adoption of electric and hybrid vehicles. According to Persistence Market Research, the market is valued at US$ 6.4 billion in 2024 and is projected to reach US$ 8.9 billion by 2031, expanding at a CAGR of 4.9% during the forecast period from 2024 to 2031.…
Digital Crosspoint Switches Market Anticipated to Hit USD 52.5 Billion by 2032
Overview of the Digital Crosspoint Switches Market
The global digital crosspoint switches market is expected to be valued at US$ 28.9 billion in 2025, with projections to reach US$ 52.5 billion by 2032, growing at a robust CAGR of 8.9% during the forecast period. This growth is fueled by the surging need for high-speed data transmission, the expansion of next-generation telecommunications networks, and the increasing deployment of data centers worldwide. As…
More Releases for Antibody
OBP2A Antibody Market Thrives on Technological Innovations in Antibody Productio …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global OBP2A Antibody Market- (By Type (Polyclonal Antibodies, and Monoclonal Antibodies; By Application-(Enzyme Linked Immunosorbent Assay, Immunohistochemistry, & Western Blot)), By Region, Trends, Industry Competition Analysis, Revenue and Forecast To 2031."
According to the latest research by InsightAce Analytic, the Global OBP2A Antibody Market is valued at US$ 102.9 Mn in 2023, and it is expected to…
Evolving Market Trends In The Antibody Drug Conjugates Industry: Regulation On A …
The Antibody Drug Conjugates Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Antibody Drug Conjugates Market Size During the Forecast Period?
The market size for antibody drug conjugates has experienced rapid expansion in the past few years. It's projected to rise from…
TIGIT Antibody Clinical Trials FDA Approval Market Size Anti TGIT Antibody Sales …
Anti TIGIT Antibodies Clinical Trials & Market Opportunity Outlook 2028 Report Highlights:
• Anti TIGIT Antibodies In Clinical Trials: > 50 Antibodies
• First Anti TIGIT Antibody To Get Approval Within Next 5 Years
• Global Anti TIGIT Antibodies Clinical Pipeline Insight By Company, Indication and Phase
• Insight On More Than 50 Anti TIGIT Antibodies In Clinical Trials
• Anti TIGIT Antibodies Market Trends by Indication & Country
• Global Anti TIGIT Antibodies Market Dynamics
Download Report:
https://www.kuickresearch.com/report-anti-tigit-antibody-anti-tigit-antibodies-fda-approved-tigit-antibody-tigit-inhibitors-tigit-drugs-approved-tigit-expression-tigit-ligand-tigit-gene
In recent years, the global…
Mammalian Polyclonal IgG Antibody Market, Mammalian Polyclonal IgG Antibody Mark …
"According to the research report, the global inspection machines market was valued at USD 845.21 million in 2022 and is expected to reach USD 1,437.59 million by 2032, to grow at a CAGR of 5.5% during the forecast period."
Request Our Free Sample Report for Inspection Machines Market Insights and Emerging Trends @ https://www.polarismarketresearch.com/industry-analysis/inspection-machines-market/request-for-sample
Report Overview
Polaris Market Research, a leading global market research and consulting company, has recently published its latest report…
Global Combination Antibody Therapy Market 2022: Antibody/Antibody Combination S …
The combination antibody therapy market is expected to experience significant growth in the coming years. Combination antibody therapy involves the use of two or more monoclonal antibodies (mAbs) in combination to treat various diseases, such as cancer, autoimmune disorders, and infectious diseases.
Request For Free Sample Report of "Combination Antibody Therapy Market"@ https://www.persistencemarketresearch.com/samples/11740
Combination antibody therapy has several potential benefits over single-agent therapies, including increased efficacy, improved patient outcomes, and reduced toxicity.…
Global Combination Antibody Therapy Market 2022: Antibody/Antibody Combination S …
Combination antibody therapy involves the use of two or more antibodies to target and treat a specific disease or condition. This type of therapy is often used in cancer treatment, as it can be more effective at targeting and killing cancer cells than single-antibody therapies. Combination antibody therapy can also be used to treat a range of other diseases and conditions, including autoimmune diseases, infectious diseases, and allergic conditions.
Request For…
